Parliamentary questions can be asked by any MSP to the Scottish Government or the Scottish Parliamentary Corporate Body. The questions provide a means for MSPs to get factual and statistical information.
Displaying 3926 questions Show Answers
To ask the Scottish Government how much has been awarded by Scottish Enterprise in business grants in each year since 2007.
To ask the Scottish Government what resources are available to Scottish Enterprise to provide grants in 2020-21.
To ask the Scottish Government how many companies have been awarded R&D grants by Scottish Enterprise in each year since 2007.
To ask the Scottish Government what the cost has been of journeys using the ministerial car pool in each year since 2007.
To ask the Scottish Government how many companies are in the pipeline to receive support funding from Scottish Enterprise.
To ask the Scottish Government, in light of the publication of the minutes of the Scottish Screening Committee meeting in November 2019, whether it will provide further details of the action it will lead on for the development of a protocol for NHS boards wishing to undertake pilot programmes for lung cancer screening.
To ask the Scottish Government what its response is to concerns that some people are ignoring the mandatory requirement to wear a face covering in shops, and how it is monitoring and enforcing this requirement.
To ask the Scottish Government what its response is to reported delays and bureaucracy that have been faced by retired GPs who have volunteered to help the NHS during the COVID-19 pandemic; whether it will investigate these delays, and how it will ensure that all retired GPs who wish to volunteer will be available to help deliver this year’s flu vaccination programme without undue delays.
To ask the Scottish Government what its response is to reports that residents in the Lothian region have been unable to access COVID-19 tests due to a lack of availability of slots at testing centres, and what action it will take to address this.
To ask the Scottish Government whether anticipated cost savings as a result of moving towards the use of non-branded and generic pharmaceutical products were a factor in the decision to remove all prescription charges, and what analysis it has conducted of cost savings as a result of moving towards the use of such products.